Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.

ABSTRACT:

Background

Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers.

Methods

This multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1 between Jul 2015 and Oct 2022. The primary endpoint was relapse-free survival (RFS). Secondary endpoints included overall survival (OS), recurrence pattern and toxicity

SUBMITTER: Bai X 

PROVIDER: S-EPMC10641479 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature